Sebastien Quetant
Overview
Explore the profile of Sebastien Quetant including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
303
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mansy L, Caille A, Reynaud-Gaubert M, Bermudez J, Bonniaud P, Borie R, et al.
Eur Respir J
. 2024 Sep;
64(3.
PMID: 39231630
No abstract available.
2.
Mismetti V, Delavenne X, Montani D, Bezzeghoud S, Delezay O, Hodin S, et al.
Respir Res
. 2023 Nov;
24(1):273.
PMID: 37936223
Background: Interstitial lung disease (ILD) and pulmonary hypertension (PH) represent the major causes of mortality in systemic sclerosis (SSc). Patients with systemic sclerosis and combined PH and ILD (SSc-PH-ILD) generally...
3.
Mabo A, Borie R, Wemeau-Stervinou L, Uzunhan Y, Gomez E, Prevot G, et al.
Thorax
. 2023 Sep;
79(1):68-74.
PMID: 37758458
Background: Autoimmune pulmonary alveolar proteinosis (aPAP) is a rare disease, predisposing to an increased risk of infection. A complete picture of these infections is lacking. Research Question: Describe the characteristics...
4.
Soumagne T, Quetant S, Guillien A, Falque L, Hess D, Aguilaniu B, et al.
Respir Med Res
. 2023 Sep;
84:101042.
PMID: 37734234
Background: Forced vital capacity (FVC) is routinely used to quantify the severity and identify the progression of idiopathic pulmonary fibrosis (IPF). Although less commonly used, lung transfer of carbon monoxide...
5.
Mankikian J, Caille A, Reynaud-Gaubert M, Agier M, Bermudez J, Bonniaud P, et al.
Eur Respir J
. 2023 May;
61(6).
PMID: 37230499
Background: Standard of care for interstitial lung disease (ILD) with a nonspecific interstitial pneumonia (NSIP) pattern proposes mycophenolate mofetil (MMF) as one of the first-step therapies while rituximab is used...
6.
Cottin V, Bonniaud P, Cadranel J, Crestani B, Jouneau S, Marchand-Adam S, et al.
Respir Med Res
. 2023 Jan;
83:100948.
PMID: 36630775
Background: Since the latest 2017 French guidelines, knowledge about idiopathic pulmonary fibrosis has evolved considerably. Methods: Practical guidelines were drafted on the initiative of the Coordinating Reference Center for Rare...
7.
Choi B, Messika J, Courtwright A, Mornex J, Hirschi S, Roux A, et al.
Clin Transplant
. 2021 Dec;
36(3):e14552.
PMID: 34856024
Introduction: Patients with short telomere-related interstitial lung disease (ILD) have worse outcomes after lung transplantation. We hypothesized that post-transplant airway complications, including dehiscence and bronchial stenosis, would be more common...
8.
Cottin V, Gueguen S, Jouneau S, Nunes H, Crestani B, Bonniaud P, et al.
Respiration
. 2021 Sep;
101(1):34-45.
PMID: 34515219
Background: There is growing evidence of gender-specific phenotypic differences among patients with idiopathic pulmonary fibrosis (IPF), which may affect patient outcomes. Objectives: We present the characteristics of patients with IPF...
9.
Fedi A, Keddache S, Quetant S, Guillien A, Antoniadis A, Soumagne T, et al.
Respiration
. 2021 Apr;
100(7):571-579.
PMID: 33849043
Background: In idiopathic pulmonary fibrosis (IPF), some physiological parameters measured during a 6-min walk test (6-MWT) impart reliable prognostic information. Sit-to-stand tests (STSTs) are field exercise tests that are easier...
10.
Burgel P, Durieu I, Chiron R, Ramel S, Danner-Boucher I, Prevotat A, et al.
Am J Respir Crit Care Med
. 2021 Feb;
204(1):64-73.
PMID: 33600738
Elexacaftor-tezacaftor-ivacaftor is a CFTR (cystic fibrosis [CF] transmembrane conductance regulator) modulator combination, developed for patients with CF with at least one Phe508del mutation. To evaluate the effects of elexacaftor-tezacaftor- ivacaftor...